On June 24, the inauguration ceremony of the Innovative Cancer Diagnosis and Treatment Center was successfully held at Hainan Haikong Lecheng Hospital (West China Lecheng Hospital of Sichuan University). As a major opening initiative, Saideite Biotechnology’s core technology—central memory T lymphocyte therapy for hepatocellular carcinoma—was officially launched at the hospital. Precisely positioned for the prevention of postoperative recurrence of hepatocellular carcinoma, this therapy marks a critical step forward in bringing domestically developed cutting‑edge immune cell therapy from addressing the challenge of high recurrence rates after solid tumor surgery to real‑world clinical application.

New Chapter Opens as West China Lecheng Cancer Center Sets Sail.

Leveraging the policy advantages of the “early implementation and pilot” program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, the Innovative Cancer Diagnosis and Treatment Center at West China Lecheng Hospital of Sichuan University has officially commenced operations. The center focuses on cutting‑edge therapies including Tcm, DC, NK, and stem cells, aiming to build a high‑level platform that integrates clinical diagnosis and treatment, translational research, and innovative applications. At the inauguration ceremony, Professor Shi Huashan, Executive Director of the center, systematically presented the research background, core mechanisms, and clinical value of the central memory T lymphocyte therapy for hepatocellular carcinoma.

The central memory T lymphocyte therapy for hepatocellular carcinoma is an autologous immune cell therapy developed by Saideite Biotechnology based on the biological properties of central memory T cells (Tcm). It has completed Phase I clinical studies, with positive data on safety and preliminary efficacy; Phase II clinical trials are currently being advanced in an orderly manner, which has laid a solid clinical foundation for the technology’s deployment at West China Lecheng.

Strong Alliance, New Ecosystem for Liver Cancer Treatment.

The launch of the central memory T lymphocyte therapy for hepatocellular carcinoma at West China Lecheng Hospital represents a model of deep integration between industry, clinical medicine, and research:

· Saideite Biotechnology, with its proprietary core cell therapy technologies protected by independent intellectual property rights, provides a cutting‑edge and safe treatment solution specifically targeting the prevention of postoperative recurrence.

· West China Lecheng Hospital, leveraging the “early implementation and pilot” policy of the Boao Lecheng Pilot Zone, has bridged the “last mile” for the clinical application of innovative technologies.

· The expert team at West China Lecheng offers authoritative academic support for the clinical translation of the technology and patient care.

Going forward, Saideite Biotechnology will continue to deepen its commitment to the field of immune cell therapy, advancing technological iteration and expanding its product pipeline. In partnership with West China Lecheng, the company aims to bring better survival prospects to patients with hepatocellular carcinoma and contribute to the high‑quality development of China’s tumor immunotherapy industry.